CUE (Cue Biopharma) YoY EPS Growth : 29.17% (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Cue Biopharma YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Cue Biopharma's YoY EPS Growth for the quarter that ended in Sep. 2024 was 29.17%.

Cue Biopharma's Earnings per Share (Diluted) for the three months ended in Sep. 2024 was $-0.17.

Cue Biopharma YoY EPS Growth Historical Data

The historical data trend for Cue Biopharma's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cue Biopharma YoY EPS Growth Chart

Cue Biopharma Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

YoY EPS Growth

Get a 7-Day Free Trial

14.43

6.02

9.62

-5.67

25.50

Cue Biopharma Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
YoY EPS Growth	Get a 7-Day Free Trial															22.58	23.68	13.79	31.03	29.17

Cue Biopharma YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Cue Biopharma's YoY EPS Growth for the fiscal year that ended in Dec. 2023 is calculated as:

	YoY EPS Growth (A: Dec. 2023 )
=	(Earnings per Share (Diluted) (A: Dec. 2023 )	-	Earnings per Share (Diluted) (A: Dec. 2022 ))	/	\| Earnings per Share (Diluted) (A: Dec. 2022 ) \|
=	(-1.11	-	-1.49)	/	\| -1.49 \|
=	25.50 %

Cue Biopharma's YoY EPS Growth for the quarter that ended in Sep. 2024 is calculated as:

	YoY EPS Growth (Q: Sep. 2024 )
=	(Earnings per Share (Diluted) (Q: Sep. 2024 )	-	Earnings per Share (Diluted) (Q: Sep. 2023 ))	/	\| Earnings per Share (Diluted) (Q: Sep. 2023 )) \|
=	(-0.17	-	-0.24)	/	\| -0.24 \|
=	29.17 %

Cue Biopharma YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Cue Biopharma's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Cue Biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cue Biopharma Inc (NAS:CUE) » Definitions » YoY EPS Growth

Comparable Companies

Traded in Other Exchanges

1UC:Germany

Address

40 Guest Street, Boston, MA, USA, 02135

Website

https://www.cuebiopharma.com

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.

Executives

Anish Suri	officer: President and CSO	40 GUEST STREET, BOSTON MA 02135
Daniel R Passeri	director, officer: CEO	40 GUEST STREET, BOSTON MA 02135
Pamela Garzone	director	C/O CUE BIOPHARMA, INC., 40 GUEST STREET, BOSTON MA 02135
Patrick Verheyen	director	C/O CUE BIOPHARMA, INC., 40 GUEST STREET, BOSTON MA 02135
Peter A Kiener	director	40 GUEST STREET, BOSTON MA 02135
Matteo Levisetti	officer: Chief Medical Officer	C/O CUE BIOPHARMA, INC., 40 GUEST STREET, BOSTON MA 02135
Frank Morich	director	40 GUEST STREET, BOSTON MA 02135
Fletcher Aaron G.l.	director	40 GUEST STREET, BOSTON MA 02135
Patricia Nasshorn	officer: Chief Business Officer	C/O WOMEN FIRST HEALTHCARE INC, 12220 EL CAMINO REAL, SAN DIEGO CA 92130
Kerri-ann Millar	officer: CFO	40 GUEST STREET, BOSTON MA 02135
Kenneth Pienta	officer: Chief Medical Officer	C/O CURIS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
Sandercock Colin	officer: SVP, General Counsel and Sec	40 GUEST STREET, BOSTON MA 02135
Tamar D Howson	director
Barry J. Simon	director	2533 SOUTH COAST HIGHWAY 101, SUITE 210, CARDIFF-BY-THE-SEA CA 92007
Frederick W Driscoll	director